BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase domain, which can be blocked by specific inhibitors, thereby providing effective treatment. This makes detection of BCR-ABL aberrations of utmost importance for diagnosis, classification and treatment of leukemia patients. BCR-ABL aberrations are currently detected by karyotyping, fluorescence in situ hybridization (FISH) or PCR techniques, which are time consuming and require specialized facilities. We developed a simple flow cytometric immunobead assay for detection of BCR-ABL fusion proteins in cell lysates, using a bead-bound anti-BCR catching antibody and a fluorochromeconjugated anti-ABL detection antibody. We noticed protein stability problems in lysates caused by proteases from mature myeloid cells. This problem could largely be solved by adding protease inhibitors in several steps of the immunobead assay. Testing of 145 patient samples showed fully concordant results between the BCR-ABL immunobead assay and reverse transcriptase PCR of fusion gene transcripts. Dilution experiments with BCR-ABL positive cell lines revealed sensitivities of at least 1%. We conclude that the BCR-ABL immunobead assay detects all types of BCR-ABL proteins in leukemic cells with high specificity and sensitivity. The assay does not need specialized laboratory facilities other than a flow cytometer, provides results within B4 h, and can be run in parallel to routine immunophenotyping.
Introduction
Chromosomal aberrations are frequently occurring oncogenic events in many types of leukemia.
1,2 The earliest described chromosomal aberration was the shortened chromosome 22, also called the Philadelphia (Ph) chromosome, which was first identified by Nowell and Hungerford in 1960 in the leukemic cells of patients with chronic myeloid leukemia (CML). 3 In 1973, Rowley 4 discovered that the Philadelphia chromosome resulted from a reciprocal translocation between chromosomes 9 and 22. The Rotterdam group of Grosveld et al. showed in 1982 that t(9;22)(q34;q11) fuses the upstream part of the BCR gene to the downstream part of the ABL gene. [5] [6] [7] This aberrant fusion gene leads to the generation of BCR-ABL fusion transcripts, which are translated into BCR-ABL fusion proteins. The oncogenic actions of the BCR-ABL fusion protein are still not completely understood, but include aberrantly increased signaling from the ABL tyrosine kinase domain, leading to increased proliferation and survival of the leukemic cells. 8, 9 The t(9;22) is not only found in CML, but also in a poor prognosis subgroup of precursor B-cell acute lymphoblastic leukemia (ALL), 3-6% in pediatric patients and 25-40% in adult patients. The vast majority of breakpoints in CML patients cluster in a small region in the middle of the BCR gene, the so-called major breakpoint cluster region (M-bcr). 7 In 1987, Hermans et al.
10,11 discovered a second breakpoint cluster in precursor-B-ALL, the so-called minor bcr (m-bcr). Later, Pane et al. 12 found a third breakpoint cluster further upstream in the BCR gene, the so-called micro bcr (m-bcr). Owing to the different positions of the m-bcr, M-bcr and m-bcr, the corresponding BCR-ABL transcripts and BCR-ABL fusion proteins differ in size, that is, p190, p210 and p230, respectively ( Figure 1 ). Virtually, all CML patients (B95%) have M-bcr breakpoints resulting in p210 fusion proteins; a small subgroup of CML patients (o5%) has m-bcr (p190) breakpoints. Approximately two thirds of the BCR-ABL positive precursor-B-ALL patients have m-bcr breakpoints and one third has M-bcr breakpoints. 13, 14 A small fraction (B1%) of acute myeloid leukemia (AML) patients also has p190 or p210 BCR-ABL fusion genes. 13 The m-bcr with p230 BCR-ABL fusion proteins is less frequently observed and was initially described to be associated with neutrophilic CML, a mild myeloproliferative disease, 12 but later, the m-bcr with p230 proteins was also found in classical CML and AML. 15, 16 In addition, several rare BCR-ABL variant fusion genes have been described, such as the variants that result in the p195, p200 and p225 BCR-ABL fusion proteins ( Figure 1 ). [17] [18] [19] The discovery that the BCR-ABL fusion proteins lead to an aberrantly increased signaling from the tyrosine kinase domain, 8, 9, 20, 21 has stimulated research on small molecules to block this kinase activity. The development of Imatinib, a specific tyrosine kinase inhibitor, has greatly improved the therapeutic strategies to inhibit the oncogenic effects of the BCR-ABL protein. [22] [23] [24] Recently, other small-molecule kinase inhibitors, such as Dasatinib and Nilotinib, have become available. [22] [23] [24] The availability of highly specific and effective treatment modalities for BCR-ABL positive leukemias has increased the pressure to provide a fast and accurate diagnosis of the BCR-ABL aberration.
Detection of t(9;22) is generally carried out at the chromosome level using karyotyping or fluorescence in situ hybridization (FISH), 20, 25 or at the mRNA level using PCR techniques. 26, 27 The availability of these techniques is generally restricted to specialized laboratories in reference centers with well-trained personnel. Furthermore, these techniques are time consuming: usually 1-2 days for FISH and PCR techniques, and even 1-2 weeks for karyotyping. A fast and reliable diagnosis is important for hospital logistics, clinical decision making and immediate assignment of the patient to the correct treatment arm. The BCR-ABL fusion epitopes form, by definition, new tumorspecific determinants. Therefore, a fast antibody-based technique for specific recognition of the leukemia-specific BCR-ABL proteins could be an attractive alternative for the DNA and RNA-based techniques. Owing to alternative splicing in the ABL Figure 1 Structure of the BCR and ABL genes with the breakpoint regions and the corresponding fusion gene transcripts. (a) The ABL gene contains one large breakpoint region (B200 kb), whereas three breakpoint regions have been found in the BCR gene: m-bcr, M-bcr and m-bcr, which are associated with the p190, p210 and p230 BCR-ABL fusion proteins. In addition several rare breakpoints have been reported (see arrows), including the v-bcr breakpoint. [17] [18] [19] (b) The three well-defined breakpoint regions in the BCR gene can produce at least eight different fusion transcripts, because of alternative splicing in the ABL gene (splicing to exon 2 or exon 3) and because the M-bcr consists of two intronic regions (intron 13 and intron 14). 13, 42 Additional BCR-ABL fusion transcripts have been described, but they are rare or only reported once. 13, [17] [18] [19] Flow cytometric immunobead assay for detection of BCR-ABL fusion proteins F Weerkamp et al gene (splicing to exon 2 or exon 3), and because the M-bcr consists of two intronic regions (intron 13 and intron 14), a total of at least eight different frequently occurring fusion sites can be identified ( Figure 1b) . We attempted to raise antibodies against the tumorspecific fusion epitopes of the BCR-ABL proteins. Indeed, polyclonal rabbit antisera could be raised against the p190 (e1-a2), p210 (e13-a2) and against p210 (e14-a2) epitopes, [28] [29] [30] and even the monoclonal antibody (MoAb), ER-FP1, was made against the p190 (e1-a2) fusion epitope. 31 These antibodies worked under denaturing conditions, such as in western blotting, but were not suited for intracellular staining in microscopy or flow cytometry. Therefore, another antibody-based approach was developed, in which a catching antibody recognizes one part of the fusion protein and a labeled detection antibody recognizes the other part of the fusion protein. Initially, we used the dipstick assay, in which the catching antibody was bound to a membrane. 32, 33 This method had a good specificity, but appeared to be too slow and too cumbersome for routine application in diagnostics. Therefore, we preferred a faster method that can be read by flow cytometry and easily applied in most hospital laboratories.
Here, we describe the development of a fast flow cytometric technique for the detection of BCR-ABL fusion proteins. In this assay, a bead-bound catching antibody recognizes the BCR part of the fusion protein and a phycoerythrin (PE)-conjugated detection antibody recognizes the ABL part of the fusion protein ( Figure 2) . 34 Only when a lysate of the patient cells contains the BCR-ABL fusion protein, the immunobeads will give a positive signal in the flow cytometer. The immunobead technology is simple and fast, implying that any laboratory experienced in flow cytometry can carry out the BCR-ABL immunobead assay.
Materials and methods

Cell lines
All leukemic cell lines used are available from the German Collection of Microorganisms and Cell cultures (DSMZ GmbH, Braunschweig, Germany), except for AR230, which was generated and kindly provided by H Wada et al. (Department of Virology, National Children's Medical Research Center, Tokyo, Japan). 35 Philadelphia chromosome positive cell lines were K562 and LAMA-84, both from CML blast crisis with the p210 BCR-ABL protein, TOM-1 from precursor-B-ALL with the p190 BCR-ABL protein and AR230 from an atypical CML with the p230 BCR-ABL protein. The following cell lines were used as BCR-ABL negative controls: 697 and RCH-ACV both with t(1;19) and E2A-PBX1 transcripts, RS4;11 and MV4-11 both with t(4;11) and MLL-AF4 transcripts, REH with t(12;21) and TEL-AML1 transcripts, KASUMI-1 with t(8;21) and AML1-ETO transcripts, NB4 with t(15;17) and PML-RARA transcripts, and ME-1 with inv(16) and CBFB-MYH11 transcripts.
Healthy controls
Blood was obtained from healthy donors after receiving the informed consent. Total white blood cells (WBC) were obtained by NH 4 Cl lysis of the erythrocytes. Peripheral blood mononuclear cells (PBMC) were obtained by ficoll separation. To mimic leukemic samples with varying tumor loads, BCR-ABL positive cell line cells were mixed at different concentrations in BCR-ABL negative cell line cells or in normal PBMC or WBC.
Patient samples
Freshly collected or frozen bone marrow or peripheral blood samples were obtained from the patients in accordance to the Declaration of Helsinki. All participants of the EuroFlow Consortium (EU-FP6 grant LSHB-CT-2006-018708) obtained approval from the local Medical Ethics Committee for secondary use of remaining diagnostic material of patients suspected to have a hematological malignancy.
Blood samples from patients suspected to have CML were exclusively processed by NH 4 Cl lysis of the erythrocytes (not by ficoll separation) to avoid selective loss of the CML cells. In case of ALL and AML samples, either NH 4 Cl lysis or ficoll separation were used for cell processing.
Antibodies for specific detection of BCR and ABL domains
The antibodies in the flow cytometric immunobead assay had to recognize all variants of the BCR-ABL fusion protein. This implied that the recognized BCR epitopes had to be located in the most upstream part of the BCR protein (5 0 of the m-bcr region; Figure 3 ) and that the ABL epitope had to be located downstream of exon 3 ( Figure 1a) .
The anti-ABL MoAb, 8E9, was generated and kindly provided by JY Wang, University of California, San Diego, USA. 36 This antibody recognizes the SH2 domain of the human ABL protein. 36 As no appropriate anti-BCR antibodies were available, we had to develop a new anti-BCR antibody. The antigen for immunization was selected using a method aiming at making an antibody that is most likely to work in flow cytometry. The antigenic epitopes had to be accessible for antibodies in the native protein configuration, they had to be non-homologous to other parts of the human genome to prevent cross-reactivity of the antibody with other human proteins and the selected epitopes should be non-homologous to the mouse to be sufficiently antigenic (Figure 3 ). The predicted protein folding, accessibility and antigenicity of the selected protein domains were determined using the programs available through the links: http://www.predictprotein.org and http://bio.dfci.harvard.edu/ Tools. Our in-house screening software (developed by Dr D de Ridder, Department of Immunology, Erasmus MC, Rotterdam, The Netherlands) was used to check the selected amino acid sequences for non-homology with the total human and murine genome: stretches of seven amino acids were checked, each screen shifting for one amino acid. According to these criteria, we selected a part of BCR exon 1 for cloning of the corresponding cDNA into the prokaryotic expression vector, pET-21b, which adds a Histidine tag to the protein ( Figure 3 ). The construct was transformed into BL21 Escherichia coli and the protein production was induced using isopropyl b-D-1-thiogalactopyranoside. The produced protein was purified using HIS-Select Nickel Affinity Gel (P6611, Sigma-Aldrich, Zwijndrecht, The Netherlands) and checked for purity on western blot. Immunizations and MoAb development were carried out using classical hybridoma techniques by Eurogentec (Liège, Belgium). Screening of mouse serum, hybridoma clones and purified antibodies was carried out using intracellular staining with immunoperoxidase on full-length BCR-ABL protein transfected into adherent monolayer COS cells. This cell-based screening method was chosen to ensure a good applicability of the selected antibody in flow cytometric staining procedures. Specificity of the obtained MoAb was checked using western blotting. Out of three hybridomas, hybridoma 3E10.C10 was selected for use in the flow cytometric immunobead assay.
Antibodies produced by hybridomas, anti-BCR (3E2.C10) and anti-ABL (8E9), were purified using protein G beads (Pierce Biotechnology, Rockford, IL, USA).
Prototype BCR-ABL immunobead assay
The prototype BCR-ABL immunobead assay used the Cytometric Bead Assay system (BD Biosciences, San José, CA, USA). C7 beads were conjugated with the anti-BCR (3E2.C10) and the anti-ABL (8E9) MoAb was conjugated with long-armed biotin (B1606, Invitrogen, Molecular Probes, Carlsbad, CA, USA) according to the manufacturer's guidelines.
The RIPA lysis buffer (50 mM Tris HCL, pH 7.5, 150 mm NaCl, 1% NP40, 0.1% sodium dodecyl sulfate without sodium deoxycholate) was used, which was supplemented with Protease Inhibitor Cocktail (Sigma-Aldrich), freshly added at the concentration recommended by the manufacturer. Cell lysates were prepared by resuspending the pelleted cells in RIPA lysis buffer (25 million cells per ml of RIPA, unless stated otherwise). After 30 min on ice, the lysate was spun down at 14 000 r.p.m. (18 000 g) for 2 min at 4 1C to remove cell debris and the supernatant was used in a cytometric bead assay. A total of 50 ml lysate and 100 ml anti-BCR beads (6000 beads in total) in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) were added to a filter plate (Multiscreen HTS filter plates, MSBVN1250, Millipore, Tullagreen, Ireland) and incubated for 1 hour at room temperature while shaking. The filter plate was washed twice with PBS containing 1% BSA and drained. The beads were resuspended in 100 ml anti-ABL (1 mg/ml in PBS with 1% BSA) and incubated for 30 min at room temperature while shaking. The filter plate was washed twice with PBS containing 1% BSA and drained. The beads were resuspended in 100 ml Streptavidin-PE (Molecular Probes, 5 mg/ml in PBS containing 1% BSA) and incubated for 10 min at room temperature while shaking. The filter plate was washed twice with PBS containing 1% BSA, and subsequently 1000 Figure 3 Selection of the BCR antigen for raising antibodies. To increase the chance of making an anti-BCR antibody that worked in flow cytometry, the BCR antigen to be used for immunization had to meet specific criteria. For this purpose, the BCR protein domains encoded by exon 1 were analyzed with various web-based programs for exposed regions (accessibility for the antibody), non-homologous regions (no crossreactivity with other human proteins) and antigenic determinants (difference between human and mouse). A cDNA fragment consisting of base pairs 708-959 (amino acids 211-293) was selected and used for protein production.
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In a second version of the prototype immunobead assay, a 'direct' staining method was used, employing PE-conjugated anti-ABL (8E9). In this protocol, 50 ml of lysate was incubated with 25 ml anti-BCR beads and 25 ml anti-ABL-PE, without intermediate washing steps.
Protease inhibitor pretreatment
To inhibit proteases before the cells were lysed, intact cells were pretreated with cell-permeable protease inhibitors. The pretreatment buffer consisted of 20 mM AEBSF (4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, Sigma; 20 ml of 1M stock in PBS) and 1 mM PMSF (phenylmethanesulfonyl fluoride, Sigma; 5 ml of 200 mM stock in ethanol) in 1 ml PBS. Pelleted cells were resuspended in 1 ml pretreatment buffer (maximum 10 7 cells/ml) and incubated for 30 min on ice. Later experiments showed that incubation for 10 min on ice was sufficient as well. Cells were spun down gently (5 min at 520 g at 4 1C), the supernatant was completely removed and the cells were immediately lysed, as described above.
Western blotting
Cell lysates were prepared in lysis buffer. Proteins were separated on a denaturing 12.5% polyacrylamide gel for 1 h and transferred to a nitrocellulose membrane. After blocking with 5% non-fat dry milk (170-6404, Bio-Rad Laboratories, Hercules, CA, USA), the nitrocellulose membranes were probed with anti-ABL 8E9 followed by a peroxidase-labeled rabbit-antimouse antibody (Dako, Glostrup, Denmark), and visualized by enhanced chemiluminescence (Amersham, GE Healthcare UK Ltd, Buckinghamshire, UK).
Subcellular fractioning with Zapoglobin
The mild lysing method with ZAP-OGLOBIN II lytic reagent (Beckman Coulter, Fullerton, CA, USA) lyses the cell membrane, but keeps the nuclear membrane fairly intact as well as the membranes of other intracellular components (for example, granule membranes).
The cells to be tested (25 Â 10 6 cells/ml lysis buffer; 1.25 Â 10 6 cells/50 ml/test) were pelleted and resuspended in a lysis buffer consisting of 0.15% ZAP-OGLOBIN II lytic reagent in BD FACSFlow (BD Biosciences), supplemented with Protease Inhibitor Cocktail (Pierce). After incubation for 1-2 min on ice, the cell lysate was centrifuged at 14 000 r.p.m. (18 000 g) for 2 min at 4 1C to pellet the nuclei, granules and other subcellular components. The supernatant was transferred to carry out the BCR-ABL immunobead assay (50 ml lysate per test).
PCR analysis of BCR-ABL transcripts
The PCR analysis of the different types of BCR-ABL fusion transcripts was carried out according to the BIOMED-1 protocols for both the reverse transcriptase step and the PCR step. The primers for m-bcr (p190) and M-bcr (p210) BCR-ABL transcripts were according to the BIOMED-1 protocol, and the primers for the m-bcr (p230) BCR-ABL transcripts were according to Boeckx et al. 16, 26 Real-time quantitative PCR was carried out according to the Europe Against Cancer (EAC) recommendations. 27, 37 Real-time quantitative PCR was carried out for checking dilution experiments, for analysis and confirmation of tumor loads in patient samples, and for assessment of BCR-ABL positivity in the EuroFlow testing, as described below.
Development of the BCR-ABL Protein Kit
The prototype BCR-ABL immunobead assay was further developed and optimized into the BCR-ABL Protein Kit for research use only (RUO) (BD Biosciences) employing the Cytometric Bead Assay system. The catching antibody was conjugated with the C6 bead and the detection antibody was directly conjugated with PE. 50 ml of lysate, carefully prepared with BD pretreatment A, BD pretreatment B, and BD lysate treatment reagents, incubated with 50 ml of capture beads and 50 ml of detection reagent for 2 h at room temperature with constant mixing and protected from light in either a filter plate or polystyrene tubes. The reaction mixture was washed with BD Cytometric Bead Assay wash buffer and subsequently acquired on a FACSCanto II or equivalent flow cytometer.
Testing of the BCR-ABL Protein Kit by the EuroFlow Consortium
The BCR-ABL Protein Kit was tested in nine EuroFlow laboratories on 145 consecutive bone marrow or blood samples of patients suspected to have CML or acute leukemia. This patient series was composed of 19 CML patients (including one patient at relapse), 78 precursor-B-ALL patients (50 children and 28 adults; including five relapsed patients), 18 T-ALL patients (including one relapsed patient), 27 AML patients (including four relapsed patients), and three patients with other hematological disorders. The EAC method was used for real-time quantitative PCR analysis of BCR-ABL transcripts in the same patient samples. 27 In addition, blood samples from 72 healthy individuals were analyzed in parallel as negative controls.
The BCR-ABL Protein Kit was used according to the recommendations of the manufacturer and beads were analyzed on a FACSCanto II (eight laboratories) or LSR II (one laboratory) flow cytometers, using BD FACSDiva software, version 6.1 (BD Biosciences). According to the manufacturer's instructions microcentrifugation of lysates (at 20 000 g) was carried out for 10 min at 4 1C. However, four laboratories did not have a refrigerated microcentrifuge and centrifuged for 2 min at room temperature. Storage of the recovered lysates at À80 1C was allowed to analyze multiple samples collectively for better comparison with several positive and negative controls.
Sensitivity testing of the BCR-ABL Protein Kit with cell lines
The sensitivity of the BCR-ABL Protein Kit was determined by analyzing serial dilutions of three cell lines, each expressing one of the three main variants of BCR-ABL: proteins: K562 (p210), TOM-1 (p190) and AR230 (p230). The cell lines were diluted in both PBMC and WBC from undiluted (100%) to concentrations as low as 0.05%. All analyses were carried out in duplicate. The mean fluorescence intensity (MFI) values detected in 100% PBMC and 100% WBC were used as negative control values.
Statistical analysis
Statistical analyses using the Mann-Whitney U test were carried out to compare mean MFI values between different BCR-ABL positive samples and between different experimental conditions (that is, centrifugation at room temperature for 2 min versus at 4 1C for 10 min and sample analysis at the same day versus overnight, that is, after 15 h). A value of Po0.05 was regarded to be statistically significant. 
Results
Validation of the BCR-ABL flow cytometric immunobead assay in cell lines
A flow cytometric immunobead assay for the detection of BCR-ABL fusion protein in cell lysates was developed. To test the specificity of the assay, a range of leukemic cell lines harboring either t(9;22) or other translocations were tested in the assay. In the novel assay, BCR-ABL positive cell lines, K562 and LAMA-84, gave very high PE-fluorescence signals, whereas all other BCR-ABL negative cell lines and normal PBMC did not (Figure 4a) , showing that the assay is highly specific and has a low background. The immunobead assay was designed to be independent of the BCR gene breakpoint to recognize all different forms of the BCR-ABL protein. To evaluate the performance of the assay in this regard, cell lines that harbor the three main forms of the BCR-ABL protein were tested, that is, TOM-1 with p190, LAMA-84 with p210, and AR230 with p230. Figure 4b shows that all three forms of BCR-ABL proteins are recognized by the bead assay, all with high PE fluorescence signals.
To test the sensitivity of the novel bead assay, the BCR-ABL positive cell line, K562, was diluted into normal PBMC at progressively decreasing concentrations. Figure 4c shows that BCR-ABL associated fluorescence signals are still distinguishable at very low concentrations (down to 0.1% K562). Such sensitivity is by far sufficient at diagnosis, when the tumor load in bone marrow is at least 25% 38 and usually over 50%.
Preliminary testing in ALL patient samples
Preliminary testing of a series of 19 frozen samples from precursor-B-ALL patients showed that all nine samples of BCR-ABL positive patients (as assessed by reverse transcriptase PCR) were also positive in the immunobead assay, whereas the ten BCR-ABL negative samples were negative in the immunobead assay (Figure 4d ). This result further confirmed the specificity of the immunobead assay.
Proteases and protease inhibition in CML cells and other mature myeloid cells
The initial testing of CML patient material gave unexpected results, as no BCR-ABL protein could be detected. Many different protocols were tested, but all were unsuccessful. Finally, we found that the CD34 þ blast fraction of the CML cells, purified either by magnetic beads or by high-speed cell sorting, did yield a positive BCR-ABL signal (data not shown). The explanation for this finding seemed to be that CML cells are maturing granulocytes that have extremely high levels of proteases in their granules in contrast to CD34 þ precursor cells, which lack protease activity. When CML cells are lysed, the proteases are released from the granules and aggressively Figure 4 Detection of the BCR-ABL fusion protein in cell lines with the prototype BCR-ABL immunobead assay. (a) Cell lysates from normal peripheral blood mononuclear cells (PBMC), and cell lines 697 with t(1;19), REH with t(12;21) and RS4,11 with t(4;11) did not give a PE fluorescence signal in the BCR-ABL immunobead assay, whereas cell lines, K562 and LAMA-84, both with t(9;22) gave a strong PE signal. (b) Cell lines TOM-1 with t(9;22) p190, LAMA-84 with t(9;22) p210 and AR230 with t(9;22) p230, representing the three major BCR-ABL breakpoints, all gave strong PE signals in the BCR-ABL immunobead assay. Cell line 697 with t(1;19) was used as negative control. (c) The BCR-ABL positive K562 cells were diluted into the BCR-ABL negative 697 cell line cells and lysates were prepared. The immunobead assay was carried out in triplicates for every sample. s/n ratio, signal to noise ratio. (d) The prototype BCR-ABL immunobead assay was carried out on a series of 19 precursor-B-ALL patients, which were also tested for the presence of BCR-ABL transcripts by PCR analysis; two cases were analyzed twice in separate tests. Full concordance was found between the two assays. s/n: signal to noise ratio.
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break down proteins in their environment. The proteases present in CML cells are primarily serine proteases (mostly elastase, proteinase 3 and cathepsin G) that are present at high concentrations (1 pg enzyme/cell). 39 To solve this protease problem, we used an artificial model system for CML: K562 cells were diluted in WBC from healthy donors. The K562 cells provide the BCR-ABL protein, whereas the granulocytes within the normal WBC contain high levels of proteases. Using this model system, we found that the fluorescence signal of 10% K562 cells, which is normally easily detectable (Figure 4c) , was completely gone when diluted in normal WBC (Figure 5a ).
Attempts to prevent protein degradation by adding several different types of protease inhibitors to the lysis buffer failed; apparently, the proteases work extremely fast on release from the granules. Finally, a solution was found: pretreatment of intact cells with cell-permeable protease inhibitors was used to inhibit the proteases before they were released by lysing the cells. Initially, diisopropyl fluorophosphate was used, 40 but this substance is neurotoxic and, thus, not suited for routine diagnostic tests. Therefore, we searched for a replacement of diisopropyl fluorophosphate and found that a combination of 20 mM AEBSF and 1 mM PMSF gave similar results (Figures 5b  and c ). This mixture of protease inhibitors was used in the prototype BCR-ABL immunobead assay till the BD pretreatment and BD lysate treatment reagents became available in the BCR-ABL Protein Kit.
Subcellular fractioning with Zapoglobin to prevent protease activity in cell lysates
In classical leukocyte counting using the Coulter Counter method (Beckman Coulter), a mild lysing method is used with ZAP-OGLOBIN II lytic reagent, which lyses the cell membrane, but keeps the nuclear membrane fairly intact so that nuclei can be counted to assess the 'nucleated' cell count, that is, the WBC (without red cells). We assumed that not only the nuclear membrane would remain intact, but also the membranes of other intracellular components, including the granules in myeloid cells.
Several experiments with 10% K562 cells in WBC showed that the classical Zapoglobin lysing method with subsequent high-speed centrifugation reduced the protease activity in the supernatant significantly in such a way that pretreatment with protease inhibitors was not necessary any more. In fact, omission of pretreatment with protease inhibitors resulted in high signals, indicating that the protease inhibition reduces the performance of the bead assay (Figure 6a ). Apparently the vast majority of the granules remained intact and could be removed from the supernatant by high-speed centrifugation. However, slightly longer incubation times (42 min) and slightly higher Zapoglobin concentrations (0.25% instead of 0.15%) completely erased the positive effect of the Zapoglobin lysing method (Figure 6b) . Additional experiments also showed batch-to-batch variations in the ZAP-OGLOBIN II lytic reagent, which were not observed when used for WBC counting. Apparently, many factors influence the differential lysis of cell membranes versus granule membranes, resulting in a very narrow window for differential lysis of membranes. This makes the Zapoglobin 
Testing of the BCR-ABL Protein Kit by the EuroFlow Consortium
The prototype BCR-ABL immunobead assay was further developed and optimized into the BCR-ABL Protein Kit by BD Biosciences (now also commercially available). (Table 1) . A total of 17 out of 78 precursor-B-ALL patients (22%) were positive for BCR-ABL with both methods (16 adult patients and one child). All 19 CML patients were BCR-ABL positive with both methods. One of these CML patients was borderline positive with the BCR-ABL Protein Kit assay (MFI of 144), but clearly positive with the prototype BCR-ABL immunobead assay. The BCR-ABL positivity of the leukemic cells in this CML patient was confirmed in a follow-up sample (B5% of leukemic cells). All other 45 acute leukemia patients (18 T-ALL and 27 AML) and three additional cases with other hematological disorders were BCR-ABL negative in both assays (Table 1) .
Different MFI values in CML and precursor-B-ALL
The MFI values of the BCR-ABL positive cases differed significantly between the 17 BCR-ABL positive precursor-B-ALL patients and the 19 CML patients (Po0.001): 15/17 (88%) precursor-B-ALL patients were highly positive using the BCR-ABL Protein Kit (MFI X1000), whereas 16/19 (84%) of CML patients were low positive (MFI: X135, but o1000); this includes the MFI value of 144 in the CML patient with borderline positivity (Figure 7 ). The significant difference in MFI values of the BCR-ABL fusion protein positivity between precursor-B-ALL and CML did not seem to be caused by the type of BCR-ABL protein (p210 versus p190), because the three 
No clear relationship between transcript levels and protein levels
To understand whether copy numbers of BCR-ABL transcripts are related to the detected levels of BCR-ABL fusion protein in the cell lysates, the MFI values of the BCR-ABL Protein Kit were plotted against the copy number of BCR-ABL transcripts, as measured by real-time quantitative PCR analysis. Remarkably, no straightforward relationship was seen between the BCR-ABL MFI values, and the ratio between BCR-ABL and control gene transcripts (data not shown). This was found for both BCR-ABL p190 and BCR-ABL p210 fusion proteins.
Microcentrifugation of cell lysate and temperature
Four of the nine EuroFlow laboratories did not use a refrigerated microcentrifuge for centrifugation of the cell lysates at 20 000 g. Therefore, we compared the MFI values of the patient samples subjected to 10 min of centrifugation at 4 1C versus patient samples subjected to 2 min of centrifugation at room temperature. When the MFI values of all BCR-ABL positive samples were evaluated, we observed a trend towards higher MFI values for samples centrifuged at 4 1C for 10 min compared with samples centrifuged at room temperature for 2 min, but this trend did not reach statistical significance (P ¼ 0.07 in MannWhitney U test) (Figure 8a ). The borderline-positive CML sample (MFI of 144) was in the 2 min room temperature group. Despite the absence of a significant difference, we advise to carry out the microcentrifugation at 4 1C.
Effect of time lapse between sampling and processing of the patient material
To understand whether longer transportation times have a negative impact on the quality and reliability of the BCR-ABL Protein Kit, all EuroFlow laboratories were asked to make a fair estimate of the time lapse between sampling and processing of the patient material. When the MFI values of all patient samples (n ¼ 145) were evaluated collectively, no clear differences were observed between time lapses. However, when only the CML Flow cytometric immunobead assay for detection of BCR-ABL fusion proteins F Weerkamp et al samples were evaluated, it seemed that processing on the same day (that is, within 9 h) resulted in higher MFI values than processing on the next day (time lapse of 18-27 h), but this difference did not reach statistical significance (P ¼ 0.06) (Figure 8b ). The borderline-positive CML sample (MFI of 144) had a time lapse of B23 h. In two EuroFlow laboratories, independent time-lapse experiments were carried out with a CML sample, which was analyzed at arrival (4-6 h), the next day (24 h) and 1 day later (48 h). In line with the results in Figure 8b , the MFI values in both samples were lower at 24 h, and were clearly reduced (borderline positive) or negative at 48 h (data not shown).
The overall results indicate that processing within 36 h (and even within 48 h) does not harm the performance of the BCR-ABL Protein Kit in acute leukemia cases. However, cell samples from patients suspected to have CML should be processed with priority, preferably on the day of sampling or on the next day at the latest, because the involved leukemic cells represent more mature myeloid cells, which contain high levels of proteases.
Sensitivity testing of the BCR-ABL Protein Kit
The sensitivity of the BCR-ABL Protein Kit was evaluated in serial dilutions of K562 (p210), TOM-1 (p190) and AR230 (p230) cells in PBMC and WBC. Duplicate experiments showed that the sensitivity reached with the AR230 (p230) and K562 (p210) cell lines was higher than that observed with the TOM-1 (p190) cell line (at least 0.1% versus at least 1%) ( Figure 9 ).
Discussion
The BCR-ABL fusion gene results from translocation t(9;22), which is the cytogenetic hallmark of CML and identifies a poorrisk subgroup of precursor-B-ALL, both in children (3-5% of cases) and in adults (25-30% of cases). The recently introduced tyrosine kinase inhibitor therapy specifically inhibits the aberrantly increased tyrosine kinase activity of the ABL kinase domain in BCR-ABL proteins, which otherwise drives the proliferation and survival of the BCR-ABL positive leukemic cells. 41 The highly effective and specific tyrosine kinase inhibitor treatment demands for 'point-of-care' diagnostics, that is, fast and easy detection of the BCR-ABL aberration in the local hospital, where the patient is diagnosed and treated. However, the BCR-ABL aberration is so far being detected by karyotyping, FISH or PCR, all techniques that are relatively time consuming and require special facilities, mainly present in specialized laboratories and consequently requiring referral of the patient samples to diagnostic reference centers.
We developed a simple flow cytometric bead assay for the detection of the BCR-ABL fusion protein in cell lysates, using a bead-bound catching antibody against one side of the fusion protein and a fluorochrome-conjugated detection antibody against the other side of the fusion protein. The anti-BCR antibody was developed against a non-homologous region of B80 amino acids, encoded by exon 1 of the BCR gene to detect all known BCR-ABL variants, including p190, p210 and p230. Indeed, the immunobead assay was able to detect all BCR-ABL variants in a set of well-defined cell lines. On the basis of the position of the BCR and ABL epitopes that are recognized by the applied antibodies, it can be anticipated that all rare and novel BCR-ABL variants will be detected by the here presented immunobead assay, 42 as was proven for the novel e18-a2 BCR-ABL (p225) variant. 19 This is in contrast to the currently used PCR techniques, which focus on the m-bcr (p190) and M-bcr (p210) breakpoints and might easily miss the p225 and p230 variants. Furthermore, the immunobead assay seemed to be specific and sufficiently sensitive to detect BCR-ABL proteins (p190 and p210) in precursor-B-ALL cell lysates. However, protein stability problems were encountered when cell samples contained high frequencies of mature myeloid cells with high levels of protease activity, such as CML cells and granulocyte fractions. Multiple experiments were carried out to reduce or exclude the protease activity in myeloid cells. Protease inhibitors had already been included in the lysis buffer, but were now also used in a pretreatment step. In addition, we investigated whether the usage of Zapoglobin as mild detergent for differential lysis of the cell membranes versus granule membranes could be a solution. Despite initially promising results, later results were too variable for easy and reliable application in a routine diagnostic setting. Finally, a showed that AR230 with p230 and K562 with p210 gave good sensitivities of at least 0.1%, whereas TOM-1 with p190 reached a sensitivity of at least 1%. The dotted line represents the mean MFI value plus 3 s.d. of the six negative samples (PBMC or WBC); this value is lower than that in Figure 7 because for this set of experiments, instrument settings were not based on the CS&T beads.
Flow cytometric immunobead assay for detection of BCR-ABL fusion proteins F Weerkamp et al combination of AEBSF and PMSF was selected as a pretreatment protease inhibitor cocktail, providing good results in CML samples.
The immunobead assay was further developed and optimized by BD Biosciences into the BCR-ABL Protein Kit with special BD pretreatment and BD lysate treatment reagents. Large scale testing of this kit in nine diagnostic laboratories of the EuroFlow Consortium showed that the results of the BCR-ABL Protein Kit were fully concordant with the PCR results in a series of 145 freshly collected samples from newly diagnosed (n ¼ 134) or relapsed (n ¼ 11) patients: 19 CML patients, 78 precursor-B-ALL patients, 18 T-ALL patients, 17 AML, and three patients with other hematological disorders. All blood samples from 72 healthy controls were negative in the assay.
The level of BCR-ABL fusion proteins differed significantly between precursor-B-ALL and CML, which was not caused by the type of BCR-ABL protein (p190 versus p210). Therefore it might well be that the majority of CML cells contain lower levels of BCR-ABL fusion protein, whereas the more immature precursor-B-ALL cells contain relatively high levels of fusion protein. Such differential expression of BCR-ABL fusion proteins might fit with the concept that CML is a hematopoietic stem cell disease, in which only early precursor cells might contain many BCR-ABL molecules, needed for maintaining the clonogenic and malignant capacity of the tumor. 43, 44 Despite this precursor cell (leukemic stem cell) theory, it might well be that the BCR-ABL fusion proteins (and other proteins) are more easily degraded in cell lysates of mature myeloid cells, which are known for their high protease content. Therefore, protease inhibition remains an important aspect of the immunobead assay, particularly needed in lysates of mature myeloid cells, such as in blood samples of patients suspected of CML. Consequently, it is wise to process CML samples fast, preferably on the day of sampling or on the next day at the latest. Ideally, the immunobead assay should contain an internal control for assessment of the protein quality in the lysate, for example, through the development of an immunobead that evaluates the integrity of a well-known (protease sensitive) 'household protein' that is ubiquitously present.
The sensitivity of the BCR-ABL Protein Kit was further tested in several dilution experiments with three different cell lines in both PBMC and WBC to mimic the various diagnostic conditions. The sensitivity was at least 1% for the TOM-1 cell line down to at least 0.1% for the K562 and AR230 cell lines. This implies that the sensitivity of the BCR-ABL immunobead assay is higher than karyotyping (B5%) and FISH (2-4%), but lower than the PCR technique.
We conclude that the flow cytometric immunobead assay is a rapid and easy technique for specific detection of BCR-ABL proteins in leukemic cells. The assay is independent of the breakpoint position in the BCR gene, does not need special laboratory facilities other than a routine flow cytometer, provides results within B4 h, and can be run in parallel to routine immunophenotyping. This is particularly important in countries, in which molecular diagnostics is not readily available for supporting patient care. The same immunobead assay can be used for detection of other fusion proteins, if the appropriate antibodies can be raised. As differentially labeled beads allow multiplexing, it will be possible to develop single tube assays for combined evaluation of multiple different fusion proteins, for example, per disease category. Consequently, the flow cytometric immunobead assay can contribute to fast and easy diagnosis and classification of leukemias. If sufficient sensitivity can be reached, monitoring of minimal residual disease may also become possible. 45 Conflict of interest F Weerkamp, E Dekking, YY Ng, KAJ Brouwer-De Cock, A van der Linden, and AL Noordijk are employees of Dynomics, a spin-off company of Erasmus MC, Rotterdam, The Netherlands; JJM van Dongen and VHJ van der Velden are inventors of the immunobead assay (patent PCT/NL01/00.945), which has been licensed by Erasmus MC to Dynomics; H Wai and R Chen are employees of BD Biosciences; FJT Staal and JJM van Dongen are stockholders of Dynomics and advised BD Biosciences in the development and optimization of the immunobead assay. It is thanks to this crucial combination of disciplines (the University setting of Erasmus MC, the spin-off company Dynomics, the Industry represented by BD Biosciences and the EuroFlow Consortium, where the clinic matches the diagnostic) that we have been provided with a complete chain of events, which has led us from invention through development and production to end up in a final clinical testing, which we present here, a first description of an innovative diagnostic product.
